Filter     Order  Title asc Title desc Ordering    Display #  5 10 15 20 25 30 50 Item Title Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas Debiopharm and EPFL honour Dr Eduard Batlle with the "Debiopharm Life Sciences Award" The Japanese Cancer Association (JCA) and Debiopharm honour Professors Masanori Hatakeyama and Johji Inazawa with the 2006 JCA-Mauvernay Award Debiopharm granted European Orphan Drugs Status for Debio-0513 (PTR-262) for Myasthenia Gravis Debiopharm and TcLand sign R&D and exclusive license option for the development of sc28AT autoimmune diseases and transplantation Debiopharm et la Haute Ecole Valaisanne collaborent pour développer les médicaments de demain Debiopharm and Dyax Corp. restructure development agreement for Depelestat (EPI-hNE4 or DX-890) in pulmonary disorders Debiopharm and EPFL launch the "Debiopharm Life Sciences Award" The Japanese Cancer Association (JCA) and Debiopharm present the inaugural 2005 JCA-Mauvernay award in Japan Debiovision Inc., a speciality pharmaceutical developer joins the Debio companies Debiovision Inc., anciennement H3 Pharma, un développeur de spécialités pharmaeutiques, se joint au groupe Debio Debiopharm and DeveloGen announce partnering of myasthenia gravis program Debiopharm and Neovacs sign License and Equity Agreement for the development fo Neovacs´ anti-TNF-Alpha product Debiopharm S.A. announces the purchase of all outstanding shares of H3 Pharma Debiopharm S.A. and GPC Biotech AG Announce Partnering of Small Molecule MHC Class II Antagonists Program for Autoimune Diseases Debiopharm S.A. and Tulane Cancer Center nominate Dr T. Curiel and Dr W. Zou, the 2004 Mauvernay Research Excellences Scholars H3 Pharma Inc. and DSM Biologics sign development agreement for SC-1 monoclonal antibody for the treatment of gastric cancer Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic Fibrosis Debiopharm S.A. and Dyax Corp. granted orphan drug designation for DX-890 (EPI-HNE4) by U.S. FDA - Cystic Fibrosis designation Debiopharm and Tulane Cancer Center select Hemenway as the 2003 Mauvernay Research Excellence Scholar   < Prev 1 2 3 Next > Results 21 - 40 of 54

Tremelimumab - codevelopment with Pfizer Inc  ( 1 items ) Debio 0931  ( 1 items ) Debio 0932  ( 2 items ) Debio 0930  ( 1 items ) Debio 0929  ( 1 items ) Debio 0928  ( 1 items ) Debio 0827  ( 1 items ) Debio 0826  ( 1 items ) Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®  ( 14 items ) Debio 8609 Sanvar®  ( 13 items ) Debio 025  ( 9 items ) Debio 9902 - ZT-1  ( 9 items ) Debio 0614 (istaroxime)  ( 2 items ) Debio 0507  ( 3 items ) Debio 0719  ( 1 items ) Debio 0617  ( 2 items ) Oxaliplatin – Eloxatin® – Elplat®  ( 10 items ) Moapar® - Salvacyl®  ( 5 items )